[Optimal pain management for cancer patients with chronic renal failure].

Autor:	Fulcrand J; UF pharmacie clinique, pôle cancérologie & spécialités médicales, centre hospitalier de Valenciennes, Valenciennes, France., Delvoye-Heiremans J; UF pharmacie clinique, pôle cancérologie & spécialités médicales, centre hospitalier de Valenciennes, Valenciennes, France., Lemaire A; Département interdisciplinaire de soins de support pour le patient oncologique, pôle cancérologie & spécialités médicales, centre hospitalier de Valenciennes, Valenciennes, France. Electronic address: lemaire-a@ch-valenciennes.fr.
Jazyk:	francouzština
Zdroj:	Bulletin du cancer [Bull Cancer] 2024 Jul-Aug; Vol. 111 (7-8), pp. 754-764. Date of Electronic Publication: 2023 Jan 31.
DOI:	10.1016/j.bulcan.2022.12.008
Abstrakt:	The management of multimorphic cancer pain is a major supportive care in oncology, for which many national and international recommendations have recently been updated. Any cancer patient must benefit from access to supportive care from the diagnosis, throughout the entire care pathway. Chronic renal failure, from any etiology, requires special attention and constant attention to details from interdisciplinary caregivers' teams to propose the best analgesic therapeutic strategy, combining complementary and interventional approaches to treatments. Analgesic therapies, in particular opioids and antineuropathics, require specific precautions. A therapeutic alliance integrating clinical pharmacy as a supportive care in its own right, is a major asset allowing the optimization and securing of analgesic drug treatments, conditioning both their efficacy, their tolerance and therapeutic observance, in the goal of improving the patient's quality of life. (Copyright © 2023 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu